Abstract：【Objective】To investigate the clinical efficacy of dapagliflozin combined with metformin hydrochloride in the treatment of type 2 diabetes(T2DM). 【Methods】A total of 87 patients with type 2 diabetes treated in our hospital from September 2020 to September 2023 were selected and divided into the observation group(treated with dapagliflozin combined with metformin hydrochloride, n=44) and the control group(treated with metformin hydrochloride, n=43) by random number table method. Fasting blood glucose(FPG), 2 h postprandial blood glucose(2hPG) and glycosylated hemoglobin(HbA1c), blood glucose standard deviation(sDBG), mean blood glucose fluctuation range(MAGE), inflammatory factors [C-reactive protein(CRP), tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), serum homocysteine(Hcy), cystatin C(cys C)], endocrine hormones [fasting insulin(Fins), pancreatic island β cell index(HOMA-β), insulin sensitivity index(HOMA-IR)], oxidative stress level [superoxide dismutase(SOD), catalase(CAT)] and incidence of adverse reactions were compared between the two groups before and after treatment. 【Results】Compared to before treatment, the levels of FPG, 2hPG, HbA1c, sDBG, MAGE, CRP, TNF-α, IL-6, Hcy and cys C in the two groups of T2DM patients decreased after treatment, while the above measurements in the observation group were significantly lower than those in the control group with statistical significance(P<0.05). Fins, SOD, CAT levels and HOMA-β of both groups increased after treatment if compared with before treatment, and their values in the observation group were significantly higher than those in the control group. The HOMA-IR of both groups decreased after treatment, and HOMA-IR level in the observation group was significantly lower than that in the control group. The difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 13.64%, compared with 23.26% in the control group, the difference was not statistically significant(χ2=1.341,P=0.247). 【Conclusion】Dapagliflozin combined with metformin hydrochloride can effectively reduce the levels of blood glucose and inflammatory factors, improve the function of islet cells in the treatment of type 2 diabetes patients, and it is safe and worthy of clinical application.
陈先乐, 章春花. 达格列净联合盐酸二甲双胍治疗2型糖尿病患者的临床疗效[J]. 医学临床研究, 2024, 41(3): 434-437.
CHEN Xianle, ZHANG Chunhua. Efficacy Analysis of Dapagliflozin Combined with Metformin in the Treatment of Patients with Type 2 Diabetes. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 434-437.
2024, Vol. 41 
